arrow
P

Paul L. den Exter

leiden university medical center
H指数:30
被引数:4,709

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Psychometric properties and outcomes of the PROMIS® Sexual Function and Satisfaction measures in individuals with congenital bleeding disorders

PROMIS®性功能与满意度量表的测量属性和结果:先天性出血障碍患者研究

2026-09-020
OAAI
A multicenter prospective observational cohort study to improve diagnostic yield and clinical management of persons with a Bleeding Disorder of Unknown Cause (BDUC-iN study protocol)

多中心前瞻性观察队列研究以提高原因不明出血性疾病患者的诊断效益和临床管理(BDUC-iN研究方案)

2026-08-010
PRE
Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening

罕见凝血因子缺乏症中的凝血酶生成分析:与出血严重程度的关联及筛查潜力

2025-12-220
OAAI
Systematic Review and Meta-analysis of the Predictive Performance of Stroke and Bleeding Prediction Models in Atrial Fibrillation Patients With Kidney Disease

系统评价和Meta分析:肾病患者心房颤动患者中风和出血预测模型的预测性能

2025-12-110
OAAI
Corrigendum to ‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’

勘误:‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’

2025-11-070
OAAI
Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: Interim Analysis of the DosEmi Study

先天性血友病A中基于药代动力学的依米珠单抗剂量调整:DosEmi研究的期中分析

2025-11-070
OAAI
Thrombectomy in high-risk pulmonary embolism – device versus thrombolysis: rationale and design of the TORPEDO-NL investigator-initiated, academically-sponsored, multicenter, open-label randomized controlled trial

高危肺栓塞患者的血栓切除 – 器械对比溶栓:TORPEDO-NL研究者发起、学术资助、多中心、开放标签随机对照试验的方案与设计

2025-08-070
OAAI
Corrigendum to “Quantitative protein mass spectrometry for multiplex measurement of coagulation and fibrinolytic proteins towards clinical application: What, why and how?”, [Thromb. Res. 241 (2024) 109090]

勘误:“Quantitative protein mass spectrometry for multiplex measurement of coagulation and fibrinolytic proteins towards clinical application: What, why and how?”, [Thromb. Res. 241 (2024) 109090]

2025-08-010
OA
Phenotype, genotype, and laboratory assessment of congenital fibrinogen disorders: Data from the Rare Bleeding disorders in the Netherlands study

表型、基因型和先天性纤维蛋白原障碍的实验室评估:来自荷兰罕见出血障碍研究的数据

2025-05-010
OAAI
Bleeding symptoms in persons with rare bleeding disorders and a heterozygous genotype: data from the Rare Bleeding Disorders in the Netherlands study

罕见出血障碍患者中携带杂合基因型的出血症状:来自荷兰罕见出血障碍研究的资料

2025-03-060
OAAI
Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical research
2025-02-010
OAAI
Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

荷兰先天性血友病A患者中基于药代动力学的依米珠单抗减量:Dosemi研究的期中分析

BLOOD
IF23.1
2024-11-050
PRE
Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives
2024-11-010
OAAI
Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin-deficient patients: Data from the Rare Bleeding disorders in the Netherlands study

alpha-2-antiplasmin-deficient患者凝血酶和纤溶酶生成谱的增强: 来自荷兰罕见出血性疾病研究的数据

2024-10-010
OAAI
Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis
2024-07-123
OAAI